Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Daiichi Sankyo’s COVID Jab Hits Mark in Japan Booster Trial, Filing Set for January
Daiichi Sankyo said on November 15 that it achieved the primary endpoint in a domestic PI/PII/PIII study designed to gauge the efficacy and safety of its mRNA vaccine DS-5670 as a booster dose against COVID-19. The company will now start…
To read the full story
Related Article
- Daiichi Sankyo Files First Home-Developed mRNA COVID Vaccine in Japan
January 16, 2023
- Daiichi Sankyo Begins PIII Primary Dose Study for mRNA COVID Jab
September 2, 2022
- COVID-19 Booster Study Shows Efficacy: Daiichi Sankyo
May 27, 2022
- Daiichi Sankyo Initiates COVID-19 Booster Study in Japan
February 1, 2022
- Daiichi Sankyo Begins PII for COVID-19 mRNA Vaccine, Eyes 2022 Rollout
November 18, 2021
- Daiichi Sankyo Eyes Booster Dose Trial Launch in January
October 22, 2021
- Daiichi Sankyo Begins Japan PI/II for mRNA COVID-19 Vaccine
March 23, 2021
BUSINESS
- SSP Looks to Broaden Switch OTC Portfolio under New President
April 13, 2026
- Otsuka Targets Around 2030 US Launch for Transcend’s PTSD Candidate
April 13, 2026
- Nippon Shinyaku, xFOREST Ink RNA-Targeting Small Molecule Research Pact
April 13, 2026
- OTC-Like Drug Reform Seen Adding 190 Billion Yen to Japan OTC Market by 2040: Fuji Keizai
April 13, 2026
- AstraZeneca Lifts Japan Approval Target to 50-Plus by 2030 as Pipeline Advances
April 13, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…